Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients.

Vitallé J, Terrén I, Orrantia A, Pérez-Garay R, Vidal F, Iribarren JA, Rodríguez C, Lirola AML, Bernal E, Zenarruzabeitia O, Borrego F.

Cell Mol Immunol. 2019 Aug 29. doi: 10.1038/s41423-019-0275-4. [Epub ahead of print] No abstract available.

PMID:
31467415
2.

Long Interleukin-22 Binding Protein Isoform-1 Is an Intracellular Activator of the Unfolded Protein Response.

Gómez-Fernández P, Urtasun A, Paton AW, Paton JC, Borrego F, Dersh D, Argon Y, Alloza I, Vandenbroeck K.

Front Immunol. 2018 Dec 14;9:2934. doi: 10.3389/fimmu.2018.02934. eCollection 2018.

3.

CD300 receptor family in viral infections.

Vitallé J, Terrén I, Orrantia A, Zenarruzabeitia O, Borrego F.

Eur J Immunol. 2019 Mar;49(3):364-374. doi: 10.1002/eji.201847951. Epub 2018 Dec 14. Review.

PMID:
30485414
4.

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers.

Vitallé J, Terrén I, Gamboa-Urquijo L, Orrantia A, Tarancón-Díez L, Genebat M, Ruiz-Mateos E, Leal M, García-Obregón S, Zenarruzabeitia O, Borrego F.

Front Immunol. 2018 Jul 23;9:1709. doi: 10.3389/fimmu.2018.01709. eCollection 2018.

5.

CD300c costimulates IgE-mediated basophil activation, and its expression is increased in patients with cow's milk allergy.

Zenarruzabeitia O, Vitallé J, Terrén I, Orrantia A, Astigarraga I, Dopazo L, Gonzalez C, Santos-Díez L, Tutau C, Gamboa PM, Bilbao A, Borrego F.

J Allergy Clin Immunol. 2019 Feb;143(2):700-711.e5. doi: 10.1016/j.jaci.2018.05.022. Epub 2018 Jun 12.

PMID:
29906528
6.

Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells.

Terrén I, Mikelez I, Odriozola I, Gredilla A, González J, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F.

Front Immunol. 2018 Apr 16;9:737. doi: 10.3389/fimmu.2018.00737. eCollection 2018.

7.

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.

Vitallé J, Zenarruzabeitia O, Terrén I, Plana M, Guardo AC, Leal L, Peña J, García F, Borrego F.

Front Immunol. 2017 Jul 21;8:836. doi: 10.3389/fimmu.2017.00836. eCollection 2017.

8.

OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors.

Herrera L, Salcedo JM, Santos S, Vesga MÁ, Borrego F, Eguizabal C.

Front Immunol. 2017 Jun 30;8:755. doi: 10.3389/fimmu.2017.00755. eCollection 2017.

9.

Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients.

Garcia-Obregon S, Azkargorta M, Seijas I, Pilar-Orive J, Borrego F, Elortza F, Boyano MD, Astigarraga I.

J Microbiol Immunol Infect. 2018 Aug;51(4):465-472. doi: 10.1016/j.jmii.2016.12.002. Epub 2017 Jun 13.

10.

Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma.

Zenarruzabeitia O, Vitallé J, Astigarraga I, Borrego F.

Clin Cancer Res. 2017 Feb 1;23(3):615-617. doi: 10.1158/1078-0432.CCR-16-2478. Epub 2016 Nov 21.

11.

The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults.

Zenarruzabeitia O, Vitallé J, García-Obregón S, Astigarraga I, Eguizabal C, Santos S, Simhadri VR, Borrego F.

Sci Rep. 2016 Sep 6;6:32693. doi: 10.1038/srep32693.

12.

27 Congreso Anual de la SETS: Bilbao (España), 23-25 Junio 2016.

Vesga MÁ, Vaquero MÁ, Bueno JL, Ezpeleta I, Oyonarte S, Sauleda S, Muñiz-Díaz E, Borrego F.

Blood Transfus. 2016 Jul 1:s367-s640. doi: 10.2450/2016.S4. [Epub ahead of print] No abstract available.

13.

Editorial: NK Cell-Based Cancer Immunotherapy.

Borrego F, Larrucea S, Solana R, Tarazona R.

Front Immunol. 2016 Jun 27;7:249. doi: 10.3389/fimmu.2016.00249. eCollection 2016. No abstract available.

14.

Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells.

Li H, Borrego F, Nagata S, Tolnay M.

J Immunol. 2016 May 15;196(10):4064-74. doi: 10.4049/jimmunol.1501027. Epub 2016 Apr 13.

15.

CD300c is uniquely expressed on CD56 bright Natural Killer Cells and differs from CD300a upon ligand recognition.

Dimitrova M, Zenarruzabeitia O, Borrego F, Simhadri VR.

Sci Rep. 2016 Apr 4;6:23942. doi: 10.1038/srep23942.

16.

The Biology and Disease Relevance of CD300a, an Inhibitory Receptor for Phosphatidylserine and Phosphatidylethanolamine.

Zenarruzabeitia O, Vitallé J, Eguizabal C, Simhadri VR, Borrego F.

J Immunol. 2015 Jun 1;194(11):5053-60. doi: 10.4049/jimmunol.1500304. Review.

17.

A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells.

Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, Muraguchi A, Kishi H, Eichelberger MC, Borrego F.

PLoS One. 2015 Apr 27;10(4):e0124677. doi: 10.1371/journal.pone.0124677. eCollection 2015.

18.

Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1.

Amo L, Tamayo-Orbegozo E, Maruri N, Eguizabal C, Zenarruzabeitia O, Riñón M, Arrieta A, Santos S, Monge J, Vesga MA, Borrego F, Larrucea S.

Front Oncol. 2014 Sep 11;4:245. doi: 10.3389/fonc.2014.00245. eCollection 2014. Review.

19.

Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective.

Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Vesga MA, Maruri N, Arrieta A, Riñón M, Tamayo-Orbegozo E, Amo L, Larrucea S, Borrego F.

Front Immunol. 2014 Sep 15;5:439. doi: 10.3389/fimmu.2014.00439. eCollection 2014. Review.

20.

Encapsulation and micronization effectively improve orange beverage flavanone bioavailability in humans.

Tomás-Navarro M, Vallejo F, Borrego F, Tomás-Barberán FA.

J Agric Food Chem. 2014 Oct 1;62(39):9458-62. doi: 10.1021/jf502933v. Epub 2014 Sep 18.

PMID:
25200135
21.

Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation.

Simhadri VR, Mariano JL, Zenarruzabeitia O, Seroogy CM, Holland SM, Kuehn HS, Rosenzweig SD, Borrego F.

J Allergy Clin Immunol. 2014 Nov;134(5):1190-3.e1. doi: 10.1016/j.jaci.2014.06.006. Epub 2014 Jul 25. No abstract available.

22.

Sudden death in incident dialysis patients.

Vázquez E, Sánchez-Perales C, García-García F, García-Cortés MJ, Torres J, Borrego F, Salas D, Liébana A, Fernandez-Guerrero JC.

Am J Nephrol. 2014;39(4):331-6. doi: 10.1159/000360547. Epub 2014 Apr 16.

23.

Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells.

Peruzzi G, Femnou L, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE.

J Immunol. 2013 Aug 15;191(4):1883-94. doi: 10.4049/jimmunol.1300313. Epub 2013 Jul 12.

24.

Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.

Zhou Q, Gil-Krzewska A, Peruzzi G, Borrego F.

Clin Exp Immunol. 2013 Jul;173(1):131-9. doi: 10.1111/cei.12095.

25.

CD300c is an activating receptor expressed on human monocytes.

Simhadri VR, Mariano JL, Gil-Krzewska A, Zhou Q, Borrego F.

J Innate Immun. 2013;5(4):389-400. doi: 10.1159/000350523. Epub 2013 Apr 6.

26.

The CD300 molecules: an emerging family of regulators of the immune system.

Borrego F.

Blood. 2013 Mar 14;121(11):1951-60. doi: 10.1182/blood-2012-09-435057. Epub 2013 Jan 4. Review.

27.

Mouse IgM Fc receptor, FCMR, promotes B cell development and modulates antigen-driven immune responses.

Choi SC, Wang H, Tian L, Murakami Y, Shin DM, Borrego F, Morse HC 3rd, Coligan JE.

J Immunol. 2013 Feb 1;190(3):987-96. doi: 10.4049/jimmunol.1202227. Epub 2012 Dec 24.

28.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

29.

Toso, a functional IgM receptor, is regulated by IL-2 in T and NK cells.

Murakami Y, Narayanan S, Su S, Childs R, Krzewski K, Borrego F, Weck J, Coligan JE.

J Immunol. 2012 Jul 15;189(2):587-97. doi: 10.4049/jimmunol.1200840. Epub 2012 Jun 6.

30.

Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a.

DeBell KE, Simhadri VR, Mariano JL, Borrego F.

BMC Immunol. 2012 Apr 26;13:23. doi: 10.1186/1471-2172-13-23.

31.

Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells.

Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F.

Blood. 2012 Mar 22;119(12):2799-809. doi: 10.1182/blood-2011-08-372425. Epub 2012 Feb 1.

32.

Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype.

Tang X, Tian L, Esteso G, Choi SC, Barrow AD, Colonna M, Borrego F, Coligan JE.

J Immunol. 2012 Jan 15;188(2):548-58. doi: 10.4049/jimmunol.1102044. Epub 2011 Dec 7.

33.

Differential expression of CD300a/c on human TH1 and TH17 cells.

Simhadri VR, Mariano JL, Zhou Q, DeBell KE, Borrego F.

BMC Immunol. 2011 Nov 2;12:62. doi: 10.1186/1471-2172-12-62.

34.

Cutting edge: mouse CD300f (CMRF-35-like molecule-1) recognizes outer membrane-exposed phosphatidylserine and can promote phagocytosis.

Choi SC, Simhadri VR, Tian L, Gil-Krzewska A, Krzewski K, Borrego F, Coligan JE.

J Immunol. 2011 Oct 1;187(7):3483-7. doi: 10.4049/jimmunol.1101549. Epub 2011 Aug 24.

35.

Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1.

Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE.

Blood. 2011 Sep 15;118(11):3019-27. doi: 10.1182/blood-2011-04-346825. Epub 2011 Aug 3.

36.

[Urinary tract infections and their prevention].

González-Chamorro F, Palacios R, Alcover J, Campos J, Borrego F, Dámaso D.

Actas Urol Esp. 2012 Jan;36(1):48-53. doi: 10.1016/j.acuro.2011.05.002. Epub 2011 Jul 14. Review. Spanish.

PMID:
21757260
37.

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Silva R, Moir S, Kardava L, Debell K, Simhadri VR, Ferrando-Martínez S, Leal M, Peña J, Coligan JE, Borrego F.

Blood. 2011 Jun 2;117(22):5870-80. doi: 10.1182/blood-2010-09-310318. Epub 2011 Apr 11.

38.

Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin.

Narayanan S, Silva R, Peruzzi G, Alvarez Y, Simhadri VR, Debell K, Coligan JE, Borrego F.

PLoS One. 2010 May 13;5(5):e10636. doi: 10.1371/journal.pone.0010636.

39.

Endocytosis and intracellular trafficking of human natural killer cell receptors.

Masilamani M, Peruzzi G, Borrego F, Coligan JE.

Traffic. 2009 Dec;10(12):1735-44. doi: 10.1111/j.1600-0854.2009.00973.x. Epub 2009 Aug 5. Review.

40.

A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens.

Tang X, Narayanan S, Peruzzi G, Apara A, Natarajan K, Margulies DH, Coligan JE, Borrego F.

J Immunol. 2009 May 1;182(9):5446-52. doi: 10.4049/jimmunol.0804052.

41.

Sleep-disordered breathing and acute stroke.

Portela PC, Fumadó JC, García HQ, Borrego FR.

Cerebrovasc Dis. 2009;27 Suppl 1:104-10. doi: 10.1159/000200447. Epub 2009 Apr 3. Review.

PMID:
19342839
42.

Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A.

Peruzzi G, Masilamani M, Borrego F, Coligan JE.

Immunol Res. 2009;43(1-3):210-22. doi: 10.1007/s12026-008-8072-7. Review.

43.

Endosomal trafficking of the ligated FcvarepsilonRI receptor.

Fattakhova GV, Masilamani M, Narayanan S, Borrego F, Gilfillan AM, Metcalfe DD, Coligan JE.

Mol Immunol. 2009 Feb;46(5):793-802. doi: 10.1016/j.molimm.2008.09.002. Epub 2008 Oct 22.

44.

Uncommon endocytic and trafficking pathway of the natural killer cell CD94/NKG2A inhibitory receptor.

Masilamani M, Narayanan S, Prieto M, Borrego F, Coligan JE.

Traffic. 2008 Jun;9(6):1019-34. doi: 10.1111/j.1600-0854.2008.00738.x. Epub 2008 Mar 19.

45.

The NKG2D receptor: immunobiology and clinical implications.

Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE.

Immunol Res. 2008;40(1):18-34. doi: 10.1007/s12026-007-0060-9. Review.

PMID:
18193361
46.

Regulation of human DAP10 gene expression in NK and T cells by Ap-1 transcription factors.

Marusina AI, Burgess SJ, Pathmanathan I, Borrego F, Coligan JE.

J Immunol. 2008 Jan 1;180(1):409-17.

47.

The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition.

Sullivan LC, Clements CS, Beddoe T, Johnson D, Hoare HL, Lin J, Huyton T, Hopkins EJ, Reid HH, Wilce MC, Kabat J, Borrego F, Coligan JE, Rossjohn J, Brooks AG.

Immunity. 2007 Dec;27(6):900-11.

48.

[Preliminary study on efficacy and tolerance of a "coupage" of olive oil in patients with chronic kidney disease. Nutritonal evaluation].

Pérez Bañasco V, Gil-Cunquero JM, Borrego FJ, Grassó M, Segura P, Warletta F, Lozano JL, Costa LA, Torres J, Gaforio JJ, Villarrubia VG.

Nefrologia. 2007;27(4):472-81. Spanish.

50.

[Nephrotic syndrome secondary to focal and segmental glomerulosclerosis in a patient with alveolar sarcoidosis].

Polaina M, Pérez del Barrio MP, Ramírez C, Borrego FJ.

Nefrologia. 2007;27(1):83-4. Spanish. No abstract available.

Supplemental Content

Loading ...
Support Center